Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-α1,3-galactose (αGal) and N-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 ± 43 months of follow-up (0.1–182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in <5% of BHV recipients within 2 years. The levels of both anti-αGal and anti-Neu5Gc IgGs significantly increased one month after BHV implantation. The levels of these IgGs declined thereafter but anti-αGal IgG levels declined significantly faster in control patients compared to BHV recipients. Neu5Gc, anti-Neu5Gc IgG and complement deposition were found in calcified BHVs at much higher levels than in calcified native aortic valves. Moreover, in mice, anti-Neu5Gc antibodies were unable to promote calcium deposition on subcutaneously implanted BHV tissue engineered to lack αGal and Neu5Gc antigens. These results indicate that BHVs manufactured using donor tissues deficient in αGal and Neu5Gc could be less prone to immune-mediated deterioration and have improved durability.

Senage, T., Paul, A., Le Tourneau, T., Fellah-Hebia, I., Vadori, M., Bashir, S., et al. (2022). The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. NATURE MEDICINE, 28(2), 283-294 [10.1038/s41591-022-01682-w].

The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration

Badano L.;
2022

Abstract

Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased heart valves but their susceptibility to structural valve degeneration (SVD) limits their use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly antibodies against the xenoantigens galactose-α1,3-galactose (αGal) and N-glycolylneuraminic acid (Neu5Gc), could mediate their deterioration through calcification. We established a large longitudinal prospective international cohort of patients (n = 1668, 34 ± 43 months of follow-up (0.1–182); 4,998 blood samples) to investigate the hemodynamics and immune responses associated with BHVs up to 15 years after aortic valve replacement. Early signs of SVD appeared in <5% of BHV recipients within 2 years. The levels of both anti-αGal and anti-Neu5Gc IgGs significantly increased one month after BHV implantation. The levels of these IgGs declined thereafter but anti-αGal IgG levels declined significantly faster in control patients compared to BHV recipients. Neu5Gc, anti-Neu5Gc IgG and complement deposition were found in calcified BHVs at much higher levels than in calcified native aortic valves. Moreover, in mice, anti-Neu5Gc antibodies were unable to promote calcium deposition on subcutaneously implanted BHV tissue engineered to lack αGal and Neu5Gc antigens. These results indicate that BHVs manufactured using donor tissues deficient in αGal and Neu5Gc could be less prone to immune-mediated deterioration and have improved durability.
Articolo in rivista - Articolo scientifico
Animals; Antibody Formation; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Humans; Immunoglobulin G; Mice; Polysaccharides; Prospective Studies; Bioprosthesis; Galactose;
English
283
294
12
Senage, T., Paul, A., Le Tourneau, T., Fellah-Hebia, I., Vadori, M., Bashir, S., et al. (2022). The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. NATURE MEDICINE, 28(2), 283-294 [10.1038/s41591-022-01682-w].
Senage, T; Paul, A; Le Tourneau, T; Fellah-Hebia, I; Vadori, M; Bashir, S; Galinanes, M; Bottio, T; Gerosa, G; Evangelista, A; Badano, L; Nassi, A; Costa, C; Cesare, G; Manji, R; Cueff de Monchy, C; Piriou, N; Capoulade, R; Serfaty, J; Guimbretiere, G; Dantan, E; Ruiz-Majoral, A; Coste du Fou, G; Leviatan Ben-Arye, S; Govani, L; Yehuda, S; Bachar Abramovitch, S; Amon, R; Reuven, E; Atiya-Nasagi, Y; Yu, H; Iop, L; Casos, K; Kuguel, S; Blasco-Lucas, A; Permanyer, E; Sbraga, F; Llatjos, R; Moreno-Gonzalez, G; Sanchez-Martinez, M; Breimer, M; Holgersson, J; Teneberg, S; Pascual-Gilabert, M; Nonell-Canals, A; Takeuchi, Y; Chen, X; Manez, R; Roussel, J; Soulillou, J; Cozzi, E; Padler-Karavani, V
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/368680
Citazioni
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
Social impact